As the global prevalence of chronic diseases, obesity and high blood glucose continues to rise, Metabolic Health has emerged as one of the fastest-growing priorities within the international health and wellness industry.
From functional nutrition and precision health management to natural bioactive peptides and GLP-1-related applications, next-generation health technologies are reshaping consumer expectations while creating new opportunities for the global healthcare market.
Organised by Greenyn Biotechnology, co-organised by THE PAGE as the exclusive official media partner, and supported by the Malaysian Dietary Supplement Association (MADSA), the Malaysia Health Market Opportunities Forum was held on August 5, 2026 at the Nexus Connexion Conference & Event Centre, Kuala Lumpur.
The forum featured a distinguished lineup of speakers from Taiwan, including: Dr. Leon Hsu, General Manager and Chief Research & Development Officer, Greenyn Biotechnology; Clara Lai, Regional Manager, International Trade Department, Greenyn Biotechnology; Dr. Sarah Tai, Deputy Manager, Product Planning Department, Greenyn Biotechnology and Dr. Ying-Chu Chen, Deputy Secretary-General, Taiwan Society of Complementary Medicine.
The speakers presented the latest scientific discoveries, market developments and future industry trends in the field of Metabolic Health.
The forum also brought together medical experts, biotechnology researchers, industry leaders, entrepreneurs, healthcare professionals and media representatives from Taiwan and Malaysia to exchange insights on global metabolic health trends, scientific innovation, product commercialisation and regional market collaboration. The event aims to strengthen bilateral industry partnerships while introducing greater international perspectives, scientific advancements and market momentum into Malaysia's rapidly growing health and wellness sector.
In recent years, the increasing prevalence of obesity, diabetes, and diabesity has accelerated the global shift toward preventive medicine, precision nutrition and naturally derived functional ingredients. Consumers are no longer seeking products that deliver a single health benefit; instead, they are demanding scientifically validated, clinically supported and comprehensive health management solutions.
As GLP-1 continues to emerge as one of the most influential trends in the global health industry, consumer demand for natural, safe and scientifically validated metabolic health solutions is growing at an unprecedented pace.
Through the Malaysia Health Market Opportunities Forum, the organisers aim to establish a strategic platform that connects scientific research, medical professionals, industry stakeholders and the marketplace. The forum is designed to accelerate the commercialisation of research breakthroughs, strengthen collaboration between the health industries of Taiwan and Malaysia, and drive the regional health sector toward greater quality, higher value creation and stronger international competitiveness.
The forum focussed on three key themes that are shaping the future of the health industry: Scientific Innovation; Consumer Application; and Market Opportunity.
Together, these themes will provide comprehensive insights into the future direction of the metabolic health industry, covering technological advancements, consumer applications and emerging market opportunities.
Participants can expect a series of exclusive presentations and industry insights, including: The first comprehensive presentation of the latest scientific findings on INSUMATE®; An exclusive preview of the newly published INSUMATE® scientific publication; In-depth analysis of global metabolic health trends and market developments; Expert presentations by leading Taiwanese specialists on the latest advances in medicine, biotechnology and functional ingredients; Introduction to the two major development directions and commercial applications of INSUMATE®.
Besides that, other highlights include Debut of a new-generation functional beauty ingredient; Business networking and collaboration opportunities between Taiwan's and Malaysia's health industries.
In addition, medical experts, scientific researchers and industry representatives from both Taiwan and Malaysia will exchange insights on clinical medicine, complementary medicine, health supplement market trends and the future of the global health industry.
These discussions are expected to strengthen the connection between scientific research, industrial applications and market demand, while fostering a more sustainable and innovation-driven health ecosystem.
Dr. Leon Hsu, CEO & Chief R&D Officer of Greenyn Biotechnology, said Malaysia has long been one of the company's key strategic markets. In recent years, the country has witnessed a steady rise in obesity, diabetes and metabolic syndrome, driving strong demand for scientifically validated functional ingredients that can effectively address the growing need for metabolic health management.
He explained that Greenyn Biotechnology has consistently focused on the research and development of natural bioactive compounds, with particular emphasis on the discovery of functional peptides, the elucidation of their mechanisms of action, and the development of innovative health applications.
To support this mission, the company has established a comprehensive scientific research platform encompassing mechanistic studies, cell-based research, animal studies and human clinical trials. This end-to-end research framework enables Greenyn to transform naturally derived bioactive molecules into clinically validated functional ingredients, providing brand partners with stronger scientific evidence and greater market competitiveness.
Among its flagship innovations is INSUMATE®, Greenyn Biotechnology's proprietary patented bitter melon peptide ingredient, powered by the world's first patented mcIRBP-19 peptide.
Unlike many conventional bitter melon products currently available in the market—which are largely based on traditional use or lack a clearly defined mechanism of action—INSUMATE® has been scientifically proven through molecular studies to bind directly to the insulin receptor, thereby activating the insulin signalling pathway.
Furthermore, INSUMATE® has undergone rigorous scientific validation through cell studies, animal research and human clinical trials, establishing a comprehensive chain of scientific evidence from molecular mechanism to demonstrated clinical efficacy.
Dr. Hsu noted that INSUMATE® has successfully completed multiple human clinical studies, been published in internationally recognised scientific journals, and secured patent protection across numerous countries.
Beyond supporting healthy blood glucose management, INSUMATE® has also demonstrated promising potential in weight management, obesity management and overall metabolic health improvement. More recently, research has revealed its potential relevance to GLP-1-related metabolic pathways, positioning INSUMATE® as a differentiated, next-generation metabolic health solution with significant commercial potential in the global marketplace.
Dr. Hsu emphasised that as global healthcare continues to shift from disease treatment toward preventive healthcare, Greenyn Biotechnology remains committed to its philosophy of "Science Creates Value."
The company provides an integrated one-stop solution, covering scientific research, formulation development, product development and commercialisation, enabling brand partners to accelerate the launch of clinically supported, market-driven health products.
Looking ahead, Dr. Hsu said Greenyn Biotechnology will continue strengthening partnerships with industry players in Malaysia and around the world through continuous scientific innovation and comprehensive product solutions. The company aims to further advance the development of the metabolic health industry while creating more opportunities for international collaboration and sustainable growth.
As the co-organiser and exclusive official media partner of the forum, THE PAGE has long been committed to promoting business trends, industry developments and international collaboration through its integrated media platform.
Darren Teoh, Publisher of THE PAGE, said that as consumers place greater emphasis on preventive healthcare, metabolic health management, functional nutrition and beauty nutrition, the health industry is entering a new era driven by scientific innovation, market education and cross-industry collaboration.
He explained that THE PAGE's decision to co-organise the Malaysia Health Market Opportunities Forum reflects the company's commitment to leveraging its media resources and industry network to connect Taiwan's biotechnology innovators with Malaysia's health industry players, brand owners, healthcare professionals and market distribution channels.
"The forum is designed not only to facilitate industry dialogue, but also to strengthen strategic collaboration between Taiwan and Malaysia while creating greater opportunities for innovation, knowledge exchange and commercial partnerships across the regional health ecosystem," he said.
"We hope this forum will serve not only as a platform for sharing the latest industry trends, but also as a bridge connecting scientific research, brands and the marketplace. By bringing valuable scientific achievements closer to industry stakeholders, we aim to strengthen collaboration between Taiwan and Malaysia while unlocking new opportunities for the future growth of the health industry."
